Daiichi Sankyo Company, Limited

Kyb Corporation

The Furukawa Electric Co., Ltd.

Kayaba Industry Company, Ltd.

Exelixis, Inc.

Keiji Saito

Katsuyoshi Nakajima

Yasuyuki Ogawa

Kaori Ito

Osamu Iwamoto

Nobuya Kurikawa

Toru Taniguchi

Eriko Kioi

Shinji Tanaka

Kazumasa Aoki

Momoko Ogitani

Natsumi Nishihama

Wataru Saitoh

Satoshi Shibuya

Tsuyoshi Mikkaichi

Seiko Nagata

Naoki Ito

Takahisa Mochizuki

Tetsuya Mieda

Takumi Asanuma

Kazuhisa Nakamura

Takashi Teraoka

Naoaki Mihara

Masami Aoyama

Hiroyuki Tsuruoka

Kunihiko Ishiguro

Toshimitsu Nakamura

Mitsuhiro Makino

Makoto Hirasawa

Takahiro Yamaguchi

Raju Mohan

Matthew A Williams

Richard Martin

John M Nuss

Takeshi Honda

Tie-Lin Wang

Atsushi Ogawa

Mitsuhiro Iwamoto

Takahiro Nagayama

Nobuyuki Ohkawa

Yutaka Mori

Yasushi Ishizaka

Tsuyoshi Soneda

Yusuke Asoh

Junya Kawai

Tsuyoshi Homma

Masatoshi Honzumi

Yuma Umezaki

Tomohiro Honda

Miho Shimada

An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: A: e.g., Benzene, E: e.g., —CH—, G: e.g., a 5-membered aromatic heterocyclic ring, X: e.g., cyclohexane, J: e.g., a 5-membered aromatic heterocyclic ring, Y: e.g., a phenyl group, R, R, R: e.g., a halogen atom, R: e.g., a C1-C6 alkyl group, R: e.g., a hydrogen atom, R, R, R, R: e.g., a hydrogen atom, R: e.g., a hydrogen atom, R: e.g., a hydrogen atom, n, n, n: e.g., 1.

Compound having cyclic structure

An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: R: e.g., a C1-C6 alkyl group; R: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R: e.g., a C1-C6 alkyl group.

Griseofulvin compound

The present invention addresses the problem of providing a compound for prophylaxis and/or treatment of central inflammatory diseases, or a pharmacologically acceptable salt thereof. The present invention addresses a compound of a general formula (I) or a pharmacologically acceptable salt thereof as a means to solve the problem. [R: a C1-C6 alkyl group or the like, R: a C1-C6 alkyl group or the like, A: a 5-membered aromatic hetero-ring or the like, R, R': a C1-C6 alkyl group or the like].

Griseofulvin compound and pharmaceutical use thereof

An object of the present invention is to provide a compound that has a specific chemical structure having an activation effect on SIRT6 and is useful as an active component for preventing and treating inflammatory diseases, and the present invention relates to a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof,

Urea compound having substituent

An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below:R: e.g., a C1-C6 alkyl group; R: a C1-C6 alkyl group;A: e.g., an oxygen atom; and R: e.g., a C1-C6 alkyl group.

An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below:A: e.g., Benzene, E: e.g., &#x2014;CH&#x2014;, G: e.g., a 5-membered aromatic heterocyclic ring, X: e.g., cyclohexane, J: e.g., a 5-membered aromatic heterocyclic ring, Y: e.g., a phenyl group, R, R, R: e.g., a halogen atom, R: e.g., a C1-C6 alkyl group, R: e.g., a hydrogen atom, R, R, R, R: e.g., a hydrogen atom, R: e.g., a hydrogen atom, R: e.g., a hydrogen atom, n, n, n: e.g., 1.

The present invention addresses the problem of providing a compound for prophylaxis and/or treatment of central inflammatory diseases, or a pharmacologically acceptable salt thereof. The present invention addresses a compound of a general formula (I) or a pharmacologically acceptable salt thereof as a means to solve the problem. [R: a C1-C6 alkyl group or the like, R: a C1-C6 alkyl group or the like, A: a 5-membered aromatic hetero-ring or the like, R, R: a C1-C6 alkyl group or the like.

The present invention provides a modified atrial natriuretic peptide that exhibits prolonged duration in blood and maintains cGMP elevating activity. The present invention provides a modified peptide in which at least one sugar substance is linked directly through a glycosidic bond or via a linker structure to at least one hANP peptide, or a pharmaceutically acceptable salt thereof, a medicament comprising the modified peptide or the salt thereof as an active ingredient, etc.

Glyco-modified atrial natriuretic peptide

An electronic-device-sealing resin composition and an organic EL element, having, as a crosslinkable organometallic desiccant, a metal complex compound having crosslinkable alkoxide represented by formula (1) as a ligand:M(OR)&#x2003;&#x2003;Formula (1) 

Resin composition for sealing electronic devices, and electronic device

Provided are a resin composition for element encapsulation for organic electronic devices which is transparent, has excellent flexibility, water vapor barrier properties, and adhesive force, and can suppress the generation of dark spots, a resin sheet for element encapsulation for organic electronic devices, an organic electroluminescent element, and an image display device. This adhesive resin composition for element encapsulation for organic electronic devices is used to seal an element for organic electronic devices, and is characterized by containing a diene polymer and a softening agent, in which the content of the softening agent is from 5% by mass to 30% by mass of the total mass.

Resin composition for element encapsulation for organic electronic devices, resin sheet for element encapsulation for organic electronic devices, organic electroluminescent element, and image display device

A piston of a magnetorheological fluid shock absorber is provided with a piston core having a small diameter portion mounted on an end portion of the piston rod, an enlarged diameter portion formed continuously in an axial direction with a diameter larger than the small diameter portion and forming a stepped portion, and a large diameter portion formed continuously in the axial direction with a diameter larger than the enlarged diameter portion and having a coil; a ring body surrounding the outer periphery of the piston core and forming a flow passage of the magnetorheological fluid between itself and the large diameter portion; a plate formed annularly and arranged on the outer periphery of the small diameter portion and mounted on one end of the ring body; and a stopper mounted on the small diameter portion and sandwiching the plate between the stopper and the stepped portion.

Magnetorheological fluid shock absorber

Growing community of inventors

Tokyo, Japan

Keiji Saito